Alnylam Pharmaceuticals | ALNY - Net Income



Alnylam Pharmaceuticals reported $-66277000 in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
Acadia Pharmaceuticals USD 26.67M 7.68M Jun/2025
Agios Pharmaceuticals USD -112020000 22.73M Jun/2025
Alnylam Pharmaceuticals USD -66277000 8.8M Jun/2025
Amgen USD 1.43B 298M Jun/2025
Arrowhead Research USD -175241000 545.69M Jun/2025
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
Incyte USD 405M 246.8M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
Moderna USD -825000000 146M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Novartis USD 4.04B 1.22B Jun/2025
PTC Therapeutics USD -64849000 931.41M Jun/2025
Regeneron Pharmaceuticals USD 1.39B 582.9M Jun/2025
Sanofi EUR 3.94B 3.44B Jun/2025
Sarepta Therapeutics USD 196.89M 644.4M Jun/2025
Takeda JPY 124.24B 227.4B Jun/2025
Tectonic Therapeutic USD -19980000 7.61M Jun/2025
Ultragenyx Pharmaceutical USD -114951000 36.13M Jun/2025
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025
Xencor USD -30825000 17.59M Jun/2025